PT2099796E - Compostos azaindolilo e métodos de utilização - Google Patents

Compostos azaindolilo e métodos de utilização Download PDF

Info

Publication number
PT2099796E
PT2099796E PT07854844T PT07854844T PT2099796E PT 2099796 E PT2099796 E PT 2099796E PT 07854844 T PT07854844 T PT 07854844T PT 07854844 T PT07854844 T PT 07854844T PT 2099796 E PT2099796 E PT 2099796E
Authority
PT
Portugal
Prior art keywords
aza
methods
indolyl compounds
indolyl
compounds
Prior art date
Application number
PT07854844T
Other languages
English (en)
Portuguese (pt)
Inventor
Mark S Stanley
Karen Williams
John Gary Montana
Simon Charles Goodacre
Stephen Price
Hazel Joan Dyke
Liang Bao
Wendy Lee
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PT2099796E publication Critical patent/PT2099796E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT07854844T 2006-11-30 2007-11-29 Compostos azaindolilo e métodos de utilização PT2099796E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86805506P 2006-11-30 2006-11-30
US91762007P 2007-05-11 2007-05-11
US94474307P 2007-06-18 2007-06-18

Publications (1)

Publication Number Publication Date
PT2099796E true PT2099796E (pt) 2011-09-06

Family

ID=39169665

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07854844T PT2099796E (pt) 2006-11-30 2007-11-29 Compostos azaindolilo e métodos de utilização

Country Status (14)

Country Link
US (1) US7855216B2 (OSRAM)
EP (1) EP2099796B1 (OSRAM)
JP (1) JP5211063B2 (OSRAM)
AR (1) AR064031A1 (OSRAM)
AT (1) ATE511509T1 (OSRAM)
AU (1) AU2007325123B2 (OSRAM)
CA (1) CA2672327A1 (OSRAM)
CL (1) CL2007003444A1 (OSRAM)
DK (1) DK2099796T3 (OSRAM)
PE (1) PE20081354A1 (OSRAM)
PL (1) PL2099796T3 (OSRAM)
PT (1) PT2099796E (OSRAM)
TW (1) TW200829586A (OSRAM)
WO (1) WO2008067481A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526267A (ja) * 2008-07-03 2011-10-06 バイエル ファーマ アクチエンゲゼルシャフト 化合物および放射性医薬品の製造方法
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
SG10201505951VA (en) * 2010-07-30 2015-08-28 Oncotherapy Science Inc Quinoline derivatives and melk inhibitors containing the same
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
KR102642411B1 (ko) * 2017-05-19 2024-02-28 엔플렉션 테라퓨틱스, 인코포레이티드 피부병 치료를 위한 피롤로피리딘-아닐린 화합물
ES2913213T3 (es) 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
US11859252B2 (en) 2017-09-08 2024-01-02 Genentech, Inc. Diagnostic and therapeutic methods for cancer
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
CN117551073A (zh) 2018-11-20 2024-02-13 恩福莱克逊治疗有限公司 用于治疗皮肤疾病噻吩基苯胺化合物
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
CN118591373A (zh) 2021-11-23 2024-09-03 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的制剂
JP2025502943A (ja) * 2022-01-28 2025-01-30 インシリコ メディシン アイピー リミテッド エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼ１（ｅｎｐｐ１）阻害剤およびその使用
CN119013276A (zh) * 2022-03-04 2024-11-22 三进制药株式会社 新型杂环化合物和包含该化合物的药物组合物
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
KR20250067072A (ko) * 2023-11-07 2025-05-14 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2003239150A1 (en) 2002-04-23 2003-11-10 Aventis Pharmaceuticals Inc. 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo
US6929411B2 (en) * 2003-09-03 2005-08-16 Hewlett-Packard Development Company, L.P. Selectable control of raster image processor
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
DE102005013621A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas

Also Published As

Publication number Publication date
AU2007325123A1 (en) 2008-06-05
US7855216B2 (en) 2010-12-21
WO2008067481A1 (en) 2008-06-05
ATE511509T1 (de) 2011-06-15
EP2099796A1 (en) 2009-09-16
EP2099796B1 (en) 2011-06-01
JP5211063B2 (ja) 2013-06-12
PL2099796T3 (pl) 2011-10-31
HK1135099A1 (en) 2010-05-28
TW200829586A (en) 2008-07-16
CA2672327A1 (en) 2008-06-05
AU2007325123B2 (en) 2012-12-13
PE20081354A1 (es) 2008-11-14
CL2007003444A1 (es) 2008-06-27
DK2099796T3 (da) 2011-09-05
AR064031A1 (es) 2009-03-04
JP2010511626A (ja) 2010-04-15
US20080242655A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
PT2099796E (pt) Compostos azaindolilo e métodos de utilização
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
IL176958A0 (en) Compounds and methods of use
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL186970A0 (en) Thiazole compounds and methods of use
GB0718972D0 (en) Compounds and methods of making the compounds
IL198397A0 (en) Anilinopiperazine derivatives and methods of use thereof
ZA200802501B (en) Indenoisoquinolinone analogs and methods of use thereof
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
IL188078A0 (en) Nano-ionic liquids and methods of use
EP2021555A4 (en) STRUCTURAL ELEMENT AND METHODS OF USE THEREOF
IL190226A0 (en) Organometallic compounds and methods of use thereof
GB0611115D0 (en) Compounds and their use
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
DK2392335T3 (en) Use of 24-norUDCA
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
IL192820A0 (en) Novel compounds and use thereof
GB0520930D0 (en) Composition and method of use
ZA200710971B (en) Elasmobranch-repelling compounds and methods of use
GB0507211D0 (en) Method and uses of compounds
AU2006907075A0 (en) Compounds and Methods of Use
ZA200903345B (en) Nitrogen-containing heterocyclic compounds and methods of use thereof